The discovery of roxithromycin is the result of a rational and scientific process, based on the fact that at least one reason for erythromycin A's resorption variability after oral administration was its instability in the gastricjuice. This instability is due to the reactivity of the ketone in position 9 in acidic medium and one chemical approach was to mask it by an oxime function. Both stereoisomers of this oxime were isolated. Direct O-alkylation of this oxime allowed access to various ether oxime derivatives and of the latter the E stereoisomers were more interesting than the Z ones. The choice of the nature of the oxime substitution was madeaccording to the lipophilic or hydrophilic character of the aliphatic ether chain and these alterations were mainly carried out by introducing heteroatoms into this chain. These different derivatives were classified in 5 groups according to the
9 in acidic medium and one chemical approach was to mask it by an oxime function. Both stereoisomers of this oxime were isolated. Direct O-alkylation of this oxime allowed access to various ether oxime derivatives and of the latter the E stereoisomers were more interesting than the Z ones. The choice of the nature of the oxime substitution was madeaccording to the lipophilic or hydrophilic character of the aliphatic ether chain and these alterations were mainly carried out by introducing heteroatoms into this chain. These different derivatives were classified in 5 groups according to the chemical nature of the chain: Aliphatic, aromatic and nitrogen-, oxygen-and sulfur-containing chains. Two classes, those containing a nitrogen or an oxygen in the ether side chains, showed differential in vitro/in vivo antibiotic activities, with improved bioavailability. Some preliminary pharmacokinetic data confirmed this improvement and led to the selection of five candidates, from which roxithromycin emerged as the best compound.
Since its discovery by McGuire et al.l) in 1952, erythromycin A (ERY) has been the most widely used and effective macrolide antibiotic against many diseases, especially respiratory tract infections including atypical pneumonia due to Legionella pneumophila, Mycoplasma pneumoniae or Chlamydia spp. Another useful indication of erythromycin is in sexually transmitted diseases, where it proves its efficiency in the treatment of non-gonococcal urethritis due to Ureaplasma urealyticum and Chlamydia trachomatis. These striking results are obtained despite unsatisfactory pharmacokinetics with a wide variability in the resorption according to the individual, an observation which is valid for all macrolides2). ERYderivatives (esters and salts) were prepared in an attempt to improve the performance, but results were disappointing. This fact led to research for newERYderivatives retaining the sameantibacterial spectral activity, but showing an improved bioavailability.
ERY(I) is an orally administered antibiotic and the main reason for its resorption variability and consequently the low antibiotic level in the serum is its instability in the gastric juice. It is well known that in acidic conditions ERYgives first an internal enolic ether and secondly an internal ketal by reaction with the ketone in position 9 and hydroxylic groups in positions 6 and 12 ( Fig. 1)3 ). Neither product exhibits antibiotic activity40 and this ketal formation is irreversible. An obvious way of preventing this internal ketalization was to block or transform the ketone group into another functional group.
The transformation of the ketone in position 9 to an oxime was a possible way of preventing internal ketalization. ERYoximes had already been described516) as well as the ester derivatives, but as the ethers were practically unexplored, we decided to prepare various ether oximes. The choice of the nature of the oximesubstitution wasmadeas a function of the lipophilic or hydrophilic character and this wascarried out mainly by introducing heteroatoms into the aliphatic ether chain, with the aim of studying structure-activity and bioavailability relationships. From a strategic point of view, we decided to systematically evaluate the activities of all products both in vitro and in vivo in the mouse in comparison with ERY, aiming at detecting the best improvement of bioavailability.
Chemistry
ERYbelongs to the 14-membered macrolide class with two carbohydrates (an amino sugar, desosamine and a neutral one, cladinose). This complex molecule is unstable in acidic mediumbut relatively stable in VOL.44 NO.3 THE JOURNAL OF ANTIBIOTICS 315 alkaline solution. The oxime derivative is easily obtained by reaction of ERYwith hydroxylamine hydrochloride in a methanol solution in the presence of triethylamine (Fig. 2 ). This reaction is complete in 24 hours of reflux. The isolated crystallized oxime (II) has the E configuration (or syn to carbon 8 of the macrolide ring) whereas in the crude product, a small proportion of the Z isomer (III) is present. By treatment in alkaline medium (NaOH, MeOH)it is possible to mainly transform the E isomer in the Z isomer. This oxime configuration was determined by NMRusing proton and 13C chemical shifts and 1 5N-13C coupling constants. The reactivity of the hydroxylic function of the oxime group enabled selective alkylation by means of alkyl halide in the presence of a base (alkaline carbonate, sodium methoxide or sodium hydride) in a solvent such as acetone, tetrahydrofuran, or ethyl ether without protection of other hydroxylic groups. In some cases the desired ethers were prepared in two steps starting from the oxime. At first a reactive ether was obtained such as the bromoethyl or oxiranylmethyl derivatives and the second step was the nucleophilic substitution of the bromine or the nucleophilic opening of the epoxide. It is possible to obtain O-alkyl oxime derivatives directly by reacting ERYwith 0-alkylhydroxylamine, but with O-methylhydroxylamine, for example, the reaction is incomplete and the yield is low. In some preparations, it was possible to obtain a di-ether derivative (V) as a minor product, substituted on the hydroxylic group of the oxime and in the 4" position on the cladinose residue, whereas no O-alkylation was observed in position 2' of the desosamine. This result is suprising, if compared with the well-known relative reactivity of different hydroxylic groups of ERY.Thus in the acylation reaction, the decreasing order ofreactivity ofhydroxylic groups is: 2',4" and 127) . In a recent paper on the preparation of 6-0-methyl ERY(TE-031), published results show that, starting from 7V-demethyl ERYN and O protected at 2' and 3' by a carbobenzyloxy group, hydroxylic groups in positions 6 and ll have the same reactivity while the hydroxyl in position 4" does not react8).
Various ether oxime derivatives of ERY(IV) have been prepared. All these derivatives were classified in 5 groups according to the chemical nature of the ether chain to compare their antimicrobial activities:
-aliphatic ether chain (Table 1)  -aromatic ether chain (Table 2) -nitrogen in the ether chain (Table 3) In vitro activity is the ratio of the geometric means of ERY/geometricmeanof the ether oximederivatives' MIC of selected sensitive microorganisms.
In vivo activity is the ratio ofPD50 of ERY/PD50 of the ether oxime derivative (in the mouse). (Table 4) -sulfur in the ether chain (Table 5) Discussion Aliphatic and aromatic oxime ether derivatives (Tables 1 and 2) show an in vitro activity comparable to that of ERYbut their in vivo activities are clearly decreased. Of the 25 nitrogen-containing oxime ether derivatives described (Table 3) , 5 compounds are more active than ERYboth in vitro and in vivo, 7 derivatives are only more active in vitro and 4 other products are more active in vivo, but less active in vitro than ERY.The length of the chain is important, as the best results were obtained with an TV-substituted ethylamine chain (ll, 12, 13, 14 and 22) In vitro activity In vivo activity 1.27 Only one sulfur-containing ether chain derivative (Table 5 , 61) showed an interesting differential activity (in vitro->in vivo).
In order to check the different derivatives having improved in vivo activity in murine experimental infections caused by Staphylococcus aureus 54146, the products were also evaluated in mouseexperimental septicaemia induced by Streptococcuspyogenes group A A561 (Table 6 ). Whereas oxygen-containing oxime ether derivatives showthe same order of in vivo activity in the course of staphylococcal (from 1.17 to 3.84 times more active than ERY) and streptococcal infections (from 2 to 5 times more active than ERY), this is not the case with nitrogen-containing oxime ether derivatives. The in vivo activities during infections induced by S. aureus remain practically the same (from 1.33 to 2.49 times more active than ERY), but the in vivo activities against S. pyogenes are clearly improved(from 1.8 to 40 times more active than ERY).
Thefact that manyderivatives present in vitro activities similar to, or moreoften weakerthan, those of ERYand that some of them are more active in vivo, demonstrates that these products have a better bioavailability. As pharmacokinetics are important in the assessment of bioavailability, we determined early on some key oral pharmacokinetic properties in comparison to ERY. These preliminary pharmacokinetics only allowed some data to be selected concerning the time (Tmax) and the concentration (Cmax) at the peak and the aspect of the curve in the elimination phase by the concentration 7 hours after administration (C at 7 hours). those of ERYin the rat. The Cmaxare several times higher than that of ERY.Whereas concentrations of all the ethers are easily detectable 7 hours after administration, ERYcannot be detected from 6 hours after administration. From a strict pharmacokinetic point of view 3 products met our objectives (13, 40 and61).
At this point, having studied 65 oxime ether derivatives of ERY, it was already possible to draw some conclusions:
-substitution of the hydroxylic group of the oxime takes place without protection of other hydroxylic groups on the macrolide ring and sugars. -two classes of ethers, nitrogen-and oxygen-containing aliphatic chains, showedremarkable
properties. -some of the nitrogen-containing oxime ether derivatives have better in vitro and in vivo activities than ERY (12/25 in vitro and 9/25 in vivo). -of the oxygen-containing oxime ether derivatives, only 2/24 are more active in vitro, while 12/24 are more active in vivo. -in experimental infection with S. pyogenes some nitrogen-containing oxime ether derivatives show very high activities (from 10 to 40 times more active than ERY). -in preliminary pharmacokinetic studies 14 ether derivatives showedclear improvement as compared toERY.
These first statements demonstrate the importance of oxime ether substitution.
Isolation of two stereoisomers of the oxime (E and Z) led us to study the influence of oxime stereochemistry on antibacterial activity. Accordingly, we prepared Z stereoisomers of derivatives 13 and 40, which are especially interesting as previously shown. In vitro and in vivo activities, reported in Table 8 , clearly indicate that all Z stereoisomers are less active.
After having considered all parameters, we selected the 5 compounds 12, 13, 34, 40, and 61 (Table  9 ) for in depth evaluation. Compounds 12 (RU 29065) and 13 (RU 29702) were chosen for their in vitro activities and their in vivo results in experimental streptococcal infection (mouse). Pharmacokinetic data of 13 were also attractive. Compounds 34 (RU 38482) and 61 (RU 40403) showed a good general profile. Compound40 (RU 28965) was selected for its important differential in vitro/in vivo activity, a consequence of its remarkable pharmacokinetics. Detailed in vitro activities of these products against selected organisms from a selection of our screening (Table 10) show that the nitrogen containing oxime ethers 12 and 13 are relatively active against Gram-negative organisms9). The most active compound in vitro against
Gram-positive organisms is 34. However, the development of a new product is long and difficult and the two nitrogen containing ether chains 12 (RU 29065) and 13 (RU 29702) had to be abandoned due to their toxicity in semi-chronic trials in rats and dogs.
In an attempt to select the best compounds from among the final three products, RU28965, RU ROXis also the best oxime ether derivative we prepared, based on physico-chemical data.
-ROXis more stable in acidic medium than ERYf.
-The methoxy ethoxy methyl chain is very important: small changes in this chain (see derivatives 35, 36, 41, 42 and 43) lead to a decrease in the in vivo activity.
-The E stereochemistry of the oxime is also essential.
-X-Ray analysis of ROX12)shows that the oxime ether chain is folded above the molecule and NMRanalysis that the conformation in solution is very similar to that of the solid state13). The position of the oxime ether chain above the plane leads to a globular structure for ROXwith respect to ERY. Such modifications of the physico-chemical characteristics have consequences on cytochrome P-450 binding and can explain why ROXdoes not interact with hepatic mono-oxygenase in vitro or in vivo14).
-In physiological conditions (37°C, pH 7.40) the octanal-water partition coefficient of ROX(P =408, Log P=2.61) indicates a more lipophilic character than ERY (P=50, Log P= 1.70)15), which can be linked with its tissue penetration16).
Experimental
In Vitro and In Vivo Studies, Serum/Plasma Level Determinations and Acute Systemic Infection Studies The in vitro activity in the tables is the ratio of the geometric mean of ERY/geometric mean of the ether oxime derivative MICs of 7 selected sensitive microorganisms (3 Staphylococci and 4 Streptococci) read after incubation at 35°C for 24 hours and measured by standard broth or agar dilution methods. The in vivo activity is expressed as the ratio of the PD50of ERY/PD50of the ether oxime derivative. To f Acid stability of roxithromycin (ROX): A comparative study of ROXand ERY was performed at 30~35°C in pH 2.6 citrate -phosphate buffer. After 2 hours' incubation, ERYwas unstable with only 16%of the compound remaining, whereas ROXwas relatively stable with 65%remaining (Fig. 3) . In pH 4.2 acetic acid -acetate buffer ROXwas completely stable for 1 hour unlike ERY, which was labile with 33% of the compound remaining. In artificial gastric juice (2g NaCl, 7 ml HC1cone, H2Ofor 1 liter-^pH 1.35), thecladinosepart ofROXwascompletelycleavedin 3 hours at25°C. MAR. 1991 determine the PD50, we used albino mice (Charles River CDX)with an average weight of 21 g, infection was produced by a 0.5-ml intraperitoneal injection of an overnight culture of the challenging organisms suitably diluted in physiological saline. The test antibiotics were suspended in 0.5 ml of water and then orally administered to groups of 10 mice (for each dose ofmacrolide) 1 hour, 5 hours and 24 hours after the bacterial challenge. The mice were observed for 7 to 10 days. The PD5Osgiven in the tables relate to experimental infection induced by S. aureus 54146. Serum levels were determined in male Sprague Dawley SPF rats (200g), after a single oral dose of 20 mg/kg. Blood samples were taken by cardiac puncture from two rats each time. Determination of antibiotic levels was carried out by using a microbiological assay and Micrococcus luteus 5345 as the test strain.
Determination of acid stability was measured in pH 2.6 citrate -phosphate buffer (0.1 m) at 30~35°C with a starting concentration of 200 jUg/ml. Samples were removed at intervals over a period of 2 hours, the pH adjusted to neutral and the amount of compound remaining dosed by reverse phase HPLC To a solution of 1.2ml of2n NaOHand 2.7ml of methanol was added 0.88g of E ERYoxime. The mixture was kept 6 hours at 25°C and overnight at 0±5°C. The mixture was evaporated to dryness. The residue was dissolved in ethyl acetate, washed with water and dried, and the solvent was removed to give 0.8 g of crude product. Crystallization from a mixture acetone-methylene chloride (3 : 4) gave 
Stereochemistry of OximeIsomers
The oxime stereochemistry was determined by NMRusing proton and 13C chemical shifts and 1 5N-13C coupling constants. All NMRmeasurements were performed on CDC13solution using a Bruker WM 250 spectrometer. Chemical shifts are in ppm from internal tetramethylsilane, coupling constants in hertz. Isotopically labeled ERYoximes were synthesised from 95%15N enriched hydroxylamine chlorhydrate. 2J 15N-13C were determined from proton decoupled 13C spectra.
XH and 13C Chemical Shifts
Chemical shifts were assigned to carbons and protons neighboring the oxime group by single frequency decoupling measurements. Results are shown in Table 12 . In the major oxime isomer H-8 is clearly deshielded and appears well separated from other protons; C-8 is shielded. Both displacements suggest an E configuration for this oxime (the oxime-OH being close to H-8 and C-8).
15N-13C Coupling Constants
According to literature17), in simple oximes these coupling constants are in the range from 7 to 12 Hz for carbons anti and from 0 to 2Hz for carbons syn to the oxime-OH. Values found in ERYoximes show that OH is syn to C-8 in the major oxime isomer (E) and syn to C-10 in the minor isomer (Z).
General Methods (£)-9-[0-(2-Methoxyethoxy)methyloxime]
of ERY (40): A mixture of 1.89 g of the oxime of ERY, 25 ml of acetone, 1 g of sodium bicarbonate and 0.36ml of (methoxyethoxy)methyl chloride was refluxed under an inert atmosphere for 75 hours during which another 0.35 ml of (methoxyethoxy)methyl chloride was added once. The mixture was vacuum filtered and the filtrate evaporated to dryness. An aqueous sodium bicarbonate solution was added to the mixture which was then extracted with ether. The organic phase was dried and evaporated to dryness and the residue was chromatographed over silica gel. Elution with a benzene -triethylamine mixture ( (2): 0.75g of sodium hydride was added to a mixture of 5.62g of the oxime of ERYand 100ml of ethyl ether and after the evolution of gas ceased, 15ml of 1,2-dibromoethane were added. The mixture was refluxed for 16 hours and was then cooled to 20°C and 0.75 g of sodium hydride was added. The mixture was refluxed for another 6 hours and after cooling it to about 0°C, 100ml ofmethylene chloride were added. 3 ml of acetic acid were then added dropwise while stirring the mixture, which was returned to room temperature before being poured into 50ml of water containing 4ml of 28% ammoniumhydroxide. The aqueous phase was extracted with methylene chloride and the combined organic phases were washed with water, dried and evaporated to dryness. The residue was chromatographed over silica gel and eluted with a methylene chloride -triethylamine mixture ( (23) (2) (£)-9-[0-(2-Methylethylamino)ethyloxime] of ERY (ll): A mixture of 2.58g of (E)-9-[O-(2-bromoethyl)oxime] of ERYand 12 ml of isopropylamine was stirred under an inert atomosphere at room temperature for 15 hours and the mixture was then poured into 600ml of water. The mixture was filtered and the recovered product was washed with water and dried to obtain 2.29g of raw product. The latter was chromatographed over silica gel and was eluted with a methylene chloride -triethylamine mixture (25 : 0.5) to obtain 1.60 g of 9-[0- (2-isopropylaminoethyl) (31): A mixture of 8.86 g of dimethylamine and 3 g of compound 38 was cooled in an ice bath and after hermetically sealing the flask, it was placed in a bath at 30~32°C. After complete dissolution, the mixture was held at 30~32°C for 74 hours and was then cooled in an ice bath. The flask was opened and the dimethylamine was removed. The residue was dried under reduced pressure to obtain 3.286g of a white solid and 3.256g of the latter was taken up in 100ml of ethyl acetate containing a little ether. The mixture was washed with water 6 times and with aqueous saturated sodium chloride solution 3 times and the organic phase was dried and evaporated to dryness under reduced pressure to obtain 3.1 g of the product. 3 g of the latter and 10ml ofpentane were stirred for 2 hours and the mixture was vacuum filtered. The recovered product was washed and dried to obtain 2.79 g of 9-[0- [(2-dimethylaminoethoxy) 
